Floatz logo

IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER

Leiomyosarcoma

OncoResponse, Inc.monoclonal_antibodyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

17 Active assets in the Leiomyosarcoma cohort.

Asset / SponsorPhaseRating
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Temsirolimus
National Cancer Institute (NCI)
Phase 2B
Cixutumumab
National Cancer Institute (NCI)
Phase 2B
vx-970
Massachusetts General Hospital
Phase 2B
Cediranib
University Health Network, Toronto
Phase 2CCC

View all 26 →

Same molecule, other indications

IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
68 / 100
View asset →
skin squamous cell carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
lung cancerDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →